Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Recovery · Sleep

DSIP (Delta Sleep-Inducing Peptide)

DSIP is a 9-amino-acid peptide first isolated from rabbit cerebral venous blood. Studied for sleep regulation, stress modulation, and circadian rhythm support.

Category: Recovery & Healing Last updated 2026-06-19
DSIP (Delta Sleep-Inducing Peptide) at a glance

DSIP is a 9-amino-acid peptide first isolated from rabbit cerebral venous blood. Studied for sleep regulation, stress modulation, and circadian rhythm support. Mechanism: Sleep-modulating nonapeptide. Typical route: Subcutaneous or intranasal. FDA status: Not FDA-approved. Available through compounding pharmacies and research-chemical suppliers; quality control varies substantially.

Drug classSleep-modulating nonapeptide
Half-life~7 minutes (parenteral)
RouteSubcutaneous or intranasal
Common dosing100-500 mcg before bed
FDA statusNot approved
Available throughCompounding pharmacies

Mechanism of action

DSIP appears to modulate the hypothalamic-pituitary-adrenal (HPA) axis, reduce stress-induced cortisol elevation, and shift sleep architecture toward more delta (deep) sleep phases. Mechanism is incompletely understood; the peptide's named function (sleep induction) is supported more in animal models than in robust human trials.

Dosing reference

Subcutaneous or intranasal: 100-500 mcg taken 30-60 minutes before bedtime. Many protocols cycle 5-7 days on, then 2-3 days off, given the unclear long-term safety profile.

Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.

FDA status & regulatory framework

Not FDA-approved. Available through compounding pharmacies and research-chemical suppliers; quality control varies substantially.

U.S. telehealth providers that work with DSIP (Delta Sleep-Inducing Peptide)

#1 of 4
88/100v3.0 six-pillar rubric

Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates DSIP (Delta Sleep-Inducing Peptide).

Read review →
#2 of 4
85/100v3.0 six-pillar rubric

Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates DSIP (Delta Sleep-Inducing Peptide).

Read review →
#3 of 4
70/100v3.0 six-pillar rubric

Starting at $110/mo. Heally is one of the providers covered in our editorial directory that dispenses or coordinates DSIP (Delta Sleep-Inducing Peptide).

Read review →
#4 of 4
71/100v3.0 six-pillar rubric

Starting at $125/mo. PeterMD is one of the providers covered in our editorial directory that dispenses or coordinates DSIP (Delta Sleep-Inducing Peptide).

Read review →

Related recovery peptides

Browse the full Recovery & Healing category →

Frequently asked questions about DSIP (Delta Sleep-Inducing Peptide)

Does DSIP actually improve sleep?

Evidence is mixed. Animal studies and small open-label human trials show modulation of sleep architecture, but well-controlled trials are limited. Some users report subjective sleep improvement; others see no effect.

Is DSIP addictive?

DSIP does not act on GABA-A receptors and is not associated with the dependence patterns seen with benzodiazepines or Z-drugs. Long-term safety data is limited.

Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
Edited by
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing